Independent sTWEAK predictors for T1DM population.

<p>Variables initially entered into this model: age, gender, smoking, physical activity, hypertension (N/Y), dyslipidemia (N/Y), BMI, WHR, SBP, DBP, logTriglycerides, logLDL-cholesterol, logHDL-cholesterol, retinopathy, nephropathy, logHb1Ac, and logeGDR.</p

Spearman correlation coefficients for the association between sTWEAK and CD163 with CVRF and low-grade inflammation.

<p>SBP, systolic blood pressure; DBP, diastolic blood pressure, MAP, mean arterial pressure; FPG, fasting plasma glucose. *p<0.05. **p<0.01.</p

Clinical characteristics of study population (men).

<p>Data are given as percentages, mean (SD) or median (interquartile range). CHD, coronary heart disease; ACR, urinary albumin/creatinine ratio.</p

Clinical characteristics of study population.

<p>Data are given as percentages, mean (SD) or median (interquartile range). CHD: Coronary heart disease. T2DM: type 2 diabetes. T1DM: type 1 diabetes. BMI: body mass index. WHR: waist-to-hip ratio. eGFR: estimation of glomerular filtration rate. ACR: Urinary albumin to creatinine ratio. PTH: parathyroid hormone. 25(OH)D: 25-hydroxy-vitamin D. FGF-23: Fibroblast growth factor 23. hsCRP: high-sensitivity C-reactive protein. IL-6: interleukin 6. sTNFαR1: soluble fraction of tumor necrosis factor α receptor 1. sTNFαR2: soluble fraction of tumor necrosis factor α receptor 2. ICAM-1: soluble intercellular adhesion molecule-1. VCAM-1: soluble vascular cell adhesion molecule-1. aPWV: aortic pulse wave velocity.</p><p>Clinical characteristics of study population.</p

Association of FGF-23 with aPWV in the patients with T1DM.

<p>Model 1 adjusted for age, sex, eGFR, current smoking (No/Yes), arterial hypertension (No/Yes), dyslipidaemia (No/Yes), BMI and FGF-23. Model 2 adjusted for covariates in model 1 and variables reflecting mineral metabolism (calcium, phosphate, PTH and 25(OH)D). Model 3 adjusted for covariates in model 2 and duration of diabetes (years) and the presence of microvascular complications (diabetic retinopathy, nephropathy and peripheral polyneuropathy) and low-grade inflammation general score and endothelial dysfunction score. 25(OH)D were additionally adjusted for seasonality.</p><p>Association of FGF-23 with aPWV in the patients with T1DM.</p

Association of FGF-23 with aPWV in the control group.

<p>Model 1 adjusted for age, sex (male/female), eGFR, current smoking (No/Yes), arterial hypertension (No/Yes), dyslipidaemia (No/Yes), BMI and FGF-23. Model 2 adjusted for covariates in model 1 and reflecting mineral metabolism (calcium, phosphate, PTH and 25(OH)D). Model 3 adjusted for covariates in model 2 and low-grade inflammation general score and ED score. 25(OH)D were additionally adjusted for seasonality.</p><p>Association of FGF-23 with aPWV in the control group.</p

Association of FGF-23 with aPWV in the whole population.

<p>Model 1 adjusted for age, sex (male/female), eGFR, current smoking (No/Yes), arterial hypertension (No/Yes), dyslipidaemia (No/Yes), BMI, TD1M (No/Yes) and FGF-23. Model 2 adjusted for covariates in model 1 and reflecting mineral metabolism (calcium, phosphate, PTH and 25(OH)D). Model 3 adjusted for covariates in model 2 and low-grade inflammation general score and ED score. 25(OH)D were additionally adjusted for seasonality.</p><p>Association of FGF-23 with aPWV in the whole population.</p